Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

32P - Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI


31 Mar 2023


Poster Display session


Jingjing Wang


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


J. Wang1, Y. Wang2

Author affiliations

  • 1 Beijing/CN
  • 2 Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 32P


SCLC transformation is one of the acquired resistance mechanisms for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. It remains unclear whether the addition of atezolizumab to chemotherapy could prolong PFS and OS of patients with SCLC transformation after EGFR-TKI treatment.


Three groups of advanced lung adenocarcinoma patients who relapsed after EGFR-TKI were analyzed in this retrospective study: cohort A included patients who did not undergo SCLC transformation and received atezolizumab plus chemotherapy after EGFR-TKI; cohort B included patients with SCLC transformation and following atezolizumab treatment; cohort C included patients who underwent SCLC transformation and did not receive atezolizumab treatment.


Twenty-six patients were enrolled in this research (cohort A: N = 6; cohort B: N = 6; cohort C: N = 14). Five of six patients in group A and all patients of group B received atezolizumab plus albumin paclitaxel-based regimens. In addition, five of six patients received atezolizumab plus albumin paclitaxel-based regimens after conventional etoposide/platinum treatment. Etoposide/platinum +/− EGFR-TKI regimens were given to all patients in group C as first-line treatment after SCLC transformation. DCR (83.3% vs 100.0%, p = 0.224) and ORR (0% vs 16.7%, p = 0.224) were similar between cohort A and cohort B. Comparable median PFS (3.5 m vs 4.7 m, p = 0.086), median OS from diagnosis of advanced stage lung cancer (33.7 m vs 54.3 m, p = 0.077), and median OS from atezolizumab implementation (6.7 vs 7.6 m, p = 0.627) were observed between group A and group B. No significant differences in median PFS between group B and group C (4.7 m vs 3.5 m, p = 0.754). Patients in cohort B presented a tendency to have better median OS from diagnosis of stage IV lung cancer (45.4 m vs 22.5 m, p = 0.180) and better median OS from SCLC transformation (24.1 m vs 11.5 m, p = 0.092) compared with cohort C.


In patients with SCLC transformation after EGFR-TKI, atezolizumab plus albumin paclitaxel-based regimen was a treatment choice after conventional etoposide/platinum regimens.

Legal entity responsible for the study

Y. Wang.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.